英国NorthStar数据库中糖皮质激素治疗与未治疗Duchenne肌营养不良男孩骨折与线性生长的全国性队列研究
该研究基于英国NorthStar数据库2006-2015年832例DMD男孩的回顾性数据,分析骨折发生率与生长情况。
要点
- 每日地夫可特治疗者线性生长受损更明显,身高SDS低1.6 SD。
核心结论
- DMD男孩骨折负担高,每日地夫可特治疗者骨折发生率最高且线性生长失败最严重。
研究设计与样本
- 回顾性队列研究,纳入英国NorthStar数据库2006-2015年832例DMD男孩,其中564例有超过1次随访。
临床怎么用
- 临床应关注DMD男孩的骨折风险与生长情况,尤其是每日地夫可特治疗者。
- 基于GC方案分层可能对骨折预防和生长改善策略是必要的。
局限性
- 回顾性研究设计。
- 未收集拒绝参与人数,但非正式数据显示拒绝率很低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Based on studies with relatively small sample size, fragility fractures are commonly reported in glucocorticoid (GC)-treated boys with Duchenne muscular dystrophy (DMD). OBJECTIVE: To determine the fracture burden and growth impairment in a large contemporary cohort of boys with DMD in the United Kingdom and in relation to GC regimen. DESIGN, SETTING, AND PARTICIPANTS: A retrospective review of fracture morbidity and growth from 832 boys with DMD in the UK NorthStar database (2006-2015), which systematically captures information from 23 participating centers. A total of 564 boys had more than 1 visit. No numbers of boys who refused were collected, but informal data from 2 centers in London and from Scotland show that refusal is very low. Data were analyzed between October 2006 and October 2015. MAIN OUTCOMES AND MEASURES: Fracture incidence rate per 10 000 person-years was determined. Cox regression analysis was used to identify factors associated with first fracture. RESULTS: Median age at baseline was 6.9 years (interquartile range, 4.9-7.2 years). At baseline, new fractures were reported in 7 of 564 participants (1.2%). During a median follow-up of 4 years (interquartile range, 2.0-6.0 years), incident fractures were reported in 156 of 564 participants (27.7%), corresponding to an overall fracture incidence rate of 682 per 10 000 person-years (95% CI, 579-798). The highest fracture incidence rate was observed in those treated with daily deflazacort at 1367 per 10 000 person-years (95% CI, 796-2188). After adjusting for age at last visit, mean hydrocortisone equivalent dose, mobility status, and bisphosphonate use prior to first fracture, boys treated with daily deflazacort had a 16.0-fold increased risk for first fracture (95% CI, 1.4-180.8; P = .03). Using adjusted regression models, change in height standard deviation scores was -1.6 SD lower (95% CI, -3.0 to -0.1; P = .03) in those treated with daily deflazacort compared with GC-naive boys, whereas there were no statistical differences in the other GC regimen. CONCLUSIONS AND RELEVANCE: In this large group of boys with DMD with longitudinal data, we document a high fracture burden. Boys treated with daily deflazacort had the highest fracture incidence rate and the greatest degree of linear growth failure. Clinical trials of primary bone protective therapies and strategies to improve growth in boys with DMD are urgently needed, but stratification based on GC regimen may be necessary.
引用
- Joseph S, Wang C, Bushby K, et al. Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database. JAMA Neurol. 2019. PMID: 30855644. doi:10.1001/jamaneurol.2019.0242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。